Comparison of the Therapeutic Efficacy of a Fixed Low-Dose Combination of Cinnarizine and Dimenhydrinate with Betahistine in Vestibular Neuritis

  title={Comparison of the Therapeutic Efficacy of a Fixed Low-Dose Combination of Cinnarizine and Dimenhydrinate with Betahistine in Vestibular Neuritis},
  author={Arne W. Scholtz and R Steindl and Nicole Burchardi and Irene Bognar-Steinberg and Wolfgang Baumann},
  journal={Clinical Drug Investigation},
AbstractBackground: Vestibular neuritis (VN) is a strongly disabling disease of the peripheral vestibular system. [] Key Method The primary endpoint was the Mean Vertigo Score (MVS) at t1w, a composite of 12 individual scores for unprovoked and provoked vertigo, each assessed using a 10 cm visual analogue scale (VAS).
Efficacy and Safety of a Fixed Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg vs Betahistine Dihydrochloride 16 mg in Patients with Peripheral Vestibular Vertigo: A Prospective, Multinational, Multicenter, Double-Blind, Randomized, Non-inferiority Clinical Trial
Evidence is provided that the fixed-combination preparation is a potent and even superior alternative to betahistine in the treatment of vertigo related to peripheral vestibular vertigo.
Fixed combination of cinnarizine and dimenhydrinate in the prophylactic therapy of vestibular migraine: an observational study
The data do not differ from those of previous works assessing efficacy of different prophylactic therapies for VM and reporting consistent reduction of vertigo spells in a rate of patients ranging from 60 and 80 %.
Cinnarizine: A Contemporary Review
Combination therapy of cinnarizine and/ or its combinations demonstrated a better safety profile than either of the mono-components, offering a viable therapeutic option in vertigo management.
Current aspects of the treatment of different types of vertigo
The efficacy of the low-dose combination drug cinnarizine + dimenhydrinate and betahistine dihydrochloride was compared in the treatment of patients with unilateral vestibular neuronitis, Meniere’s disease, and other diseases of the peripheral and central Vestibular system.
Management of peripheral vertigo with antihistamines: New options on the horizon
Encouraging outcomes in an induced vertigo model in healthy volunteers have led to ongoing clinical studies in acute unilateral vestibulopathy, with the hope that H4 antagonists will offer new effective therapeutic options to patients suffering from vertigo.
Cinnarizine and dimenhydrinate in the treatment of vertigo in medical practice
The results indicate a good tolerability and efficacy of the fixed combination of cinnarizine and dimenhydrinate in the treatment of vertigo in daily medical practice, which is in line with previous findings of numerous interventional, randomised, double-blind, controlled clinical trials.
Betahistine treatment in managing vertigo and improving vestibular compensation: clarification.
  • M. Lacour
  • Medicine, Biology
    Journal of vestibular research : equilibrium & orientation
  • 2013
Clinical data from vestibular loss patients show the impact of betahistine treatment for the long-term control of vertigo, improvement of balance and quality of life that can be explained by these mechanisms of action.
Antivertiginous drug therapy does not hinder the efficacy of individualized vibrotactile neurofeedback training for vestibular rehabilitation – a randomized trial
  • D. Basta, L. Borsellino, A. Ernst
  • Medicine, Psychology
    International journal of rehabilitation research. Internationale Zeitschrift fur Rehabilitationsforschung. Revue internationale de recherches de readaptation
  • 2017
The present results indicate that IVNT even in combination with an antivertiginous drug therapy is an effective treatment regime for patients with disabling vertigo of different origins.
Cinnarizine for the prophylaxis of migraine associated vertigo: a retrospective study
This study suggests that cinnarizine is safe and effective in reducing both headache and vertigo aspects of “migraine plus vertigo” among the patients who suffer from either vestibular migraine or migraine with brainstem aura associated with vertigo.
The Challenges of Studying Peripheral Vestibular Vertigo
In this study, the authors chose a 4-week timeframe over which to determine treatment response, and while the authors note this as a limitation specifically in regard to Meniere’s Disease, most of the peripheral vestibular disorder symptoms improve over time due to central compensation.


Efficacy and Tolerability of a Fixed Combination of Cinnarizine and Dimenhydrinate versus Betahistine in the Treatment of Otogenic Vertigo
The fixed combination of cinnarizine and dimenhydrinate was shown to be an effective and very well tolerated treatment option for patients with otogenic vertigo and proved to be statistically more efficient in reducing vertigo than the widely used betahistine.
A Fixed Combination of Cinnarizine/Dimenhydrinate for the Treatment of Patients with Acute Vertigo Due to Vestibular Disorders
The fixed combination of cinnarizine/dimenhydrinate was shown to be an effective and very well tolerated treatment option for patients with acute vertigo due to vestibular disorders and proved to be significantly more efficient in reducing vertigo and associated vegetative symptoms than betahistine in such patients.
Efficacy and Tolerability of a Fixed Combination of Cinnarizine and Dimenhydrinate in Treatment of Vertigo
Because of a significantly superior efficacy in comparison with its active constituents given alone, as well as compared with the standard monotherapies using CZ 50, DH 100 and BH, the fixed-combination ARL can be considered as a first-line treatment option for vertigo.
Fixed combination of cinnarizine and dimenhydrinate versus betahistine dimesylate in the treatment of Ménière's disease: a randomized, double-blind, parallel group clinical study.
The combination preparation proved to be a highly efficient and safe treatment option for Ménière's disease and may be used both in the management of acute episodes and in long-term treatment.
Prednisone Treatment for Vestibular Neuritis
Prednisone therapy might enhance earlier recovery but does not improve the long-term prognosis of VN, and both clinical and laboratory parameters in VN are not correlated.
Betahistine Treatment Improves the Recovery of Static Symptoms in Patients With Unilateral Vestibular Loss
Results indicate that betahistine reduces the time to recovery by 1 month or more depending on the tested functions, and the observed clinical effects may be attributed to an action of bethistine in rebalancing the neuronal activity between contralateral vestibular nuclei.
The beneficial effect of methylprednisolone in acute vestibular vertigo.
It is concluded that methylprednisolone is much more effective than placebo in reducing vertiginous symptoms in patients with acute vestibular vertigo.
Betahistine in the treatment of Ménière’s disease
The clinical efficacy of betahistine has been demonstrated in double-blind, randomized, placebo, and active controlled studies in adequate numbers of patients and the efficacy of other drugs used in treatment are equivocal.